The Global Resource for Advancing Cancer Education (GRACE), presents Molecular Diagnostic Testing and Next Generation Sequencing in Lung Cancer webinar series.
Download slides from LIVE WEBCAST of November 18, 2017 in partnership with Georgetown University Hospital, GRACE presents: 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know
Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses if there is a role for PD-L1 testing after first line treatment.
Written by Joshua Bauml, MD
September 2017
“Head and neck cancer” is an umbrella term for different cancers that occur in the head and neck region, from the sinuses and nasal cavity down to the larynx. The most common of these tumors affect the lining of the mouth and throat. Head and neck cancers are divided by where they start:
Oral cavity (tongue, gums, inner cheek)
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Many physicians worship evidence-based medicine, which is generally a very good practice that ensures that medical practice isn’t dictated by our biases and assumptions but rather on interventions that we have proven show benefits that exceed their anticipated risks.
On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center for a full day of discussion on Targeted Therapies in Lung Cancer. We are thrilled that people joined us for this amazing and informative day. Huge thanks to all of the faculty who spent their Saturday in Cleveland with our community, and thanks also to those organizations who sponsored this event - Astra Zeneca, Takeda, Boehringer Ingelheim, Ignyta, Novartis, Genentech, Caris, and Guardant Health.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for Broad Next Generation Sequencing Testing.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for EGFR.
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The agent Zykadia (ceritinib), a "second generation" ALK inhibitor that is more effective than Xalkori (crizotinib) in lab models of ALK-positive NSCLC, and the new approval was for Zykadia as first line treatment for ALK-positive lung cancer, a setting where we have historically favored Xalkori since it was approved in 2011. .
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock